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Managing Newborn Hyperbilirubinemia and 
Preventing Kernicterus  
 
Bilirubin is the yellow breakdown product created from the destruction of hemoglobin in 
circulating red blood cells; they have a shortened lifespan in the newborn. Approximately 
35 mg of unconjugated bilirubin is formed from each gram of hemoglobin, and newborns 
produce up to 10 mg/dl/day. Bilirubin production is elevated in the first 24-48 hours of 
life. Unconjugated bilirubin is lipid-soluble and must be transported to the liver in plasma, 
reversibly bound to albumin. In the liver, bilirubin is transported across hepatic cell 
membranes where it is bound to ligandin for conjugation. A liver enzyme conjugates 
bilirubin, converting it to water-soluble bilirubin pigments that can be excreted into the 
bile and urine. It is eliminated from the body via the intestines and to a lesser degree 
through the renal system. Bilirubin pigments that are not eliminated can be reabsorbed 
into the circulation as unconjugated bilirubin, a process called enterohepatic recirculation. 
In term newborns, conjugation is delayed during the first hours after birth but increases by 
about 24 hours of age. Hemolysis or bruising at birth can increase the bilirubin load. 
Elimination of bilirubin is often delayed in preterm infants. Other factors can impair its 
elimination, such as poor feeding, bowel obstruction or immature liver conjugation. 
Breastfed babies typically have higher bilirubin levels than formula fed infants.  Babies 
with reduced conjugation or elimination of bilirubin are at risk for hyperbilirubinemia.  
 
Definitions 
• Total serum bilirubin (TSB): Bilirubin is the catabolic product of heme 
metabolism, which is formed by the breakdown of heme present in hemoglobin, 
myoglobin, cytochromes, catalase, peroxidase, and tryptophan pyrrolase. Several 
laboratory techniques have been developed for measuring the serum bilirubin 
concentration. The specific technique used has implications for the interpretation 
of serum values. 
 
• Direct or conjugated bilirubin: concentration of bilirubin conjugated with 
glucuronic acid 
• Indirect or unconjugated bilirubin: the lipid-soluble form of bilirubin that 
circulates in loose association with the plasma proteins 
• Transcutaneous bilirubin (TcB): noninvasive measure of the yellow color of 
blanched skin and subcutaneous tissue; used as screening tool to help determine 
whether the TSB should be measured; provides an estimate of the TSB value 
expressed in mg/dl; measurements can be plotted on the same nomogram as TSB 
measurements 
• Hyperbilirubinemia: TSB level of <13 mg/dl or a TSB rise of <0.5 mg/dl/hour; 
results in physiologic jaundice 
• Physiologic jaundice: yellow color in skin and sclera that appears as bilirubin 
levels increase; begins cephalically, usually seen in face first and progresses 
caudally to trunk and extremities 
• Severe hyperbilirubinemia: TSB above the 95th percentile for age in hours; requires 
treatment with phototherapy 
• Phototherapy: visible light delivered in measurable doses; causes 
photoisomerization whereby bilirubin present in superficial capillaries and 
interstitial spaces of the skin and subcutaneous tissues is converted to water-
soluble isomers that are excretable without further metabolism by the liver 
• Intensive phototherapy: implies irradiance in the blue-green spectrum (wavelength 
band of approximately 430-490 nm) of at least 30 µW/cm2 per nm (measured at 
the infant’s skin directly below the center of the phototherapy unit) and delivered 
to as much of the infant’s surface area as possible; the most efficient units 
positioned for maximum skin coverage can lower TSB by as much as 5 mg/dl/hour  
• “Bronze baby syndrome”: complication of phototherapy where a grayish-brown 
discoloration of the skin occurs; seen exclusively in infants with an elevated direct-
reacting or conjugated bilirubin level (cholestatic jaundice) 
• Acute bilirubin encephalopathy (ABE): acute and reversible clinical manifestations 
of bilirubin neurotoxicity caused by an accumulation of unconjugated bilirubin in 
the brain; seen in the first weeks after birth; presenting signs are subtle and 
nonspecific; early signs include lethargy, hypotonia and poor suck; intermediate 
phase is characterized by moderate stupor, irritability and hypertonia manifested 
by backward arching of the neck (retrocollis) and trunk (opisthotonos); infant may 
develop fever and high-pitched cry which alternates with drowsiness and 
hypotonia; advanced phase may be irreversible and is characterized by pronounced 
retrocollis-opisthotonos, shrill cry, no feeding, apnea, fever, deep stupor to coma, 
possible seizures and death 
• Kernicterus: yellow staining of specific areas of brain tissue caused by an 
accumulation of unconjugated bilirubin in the brain; results in bilirubin 
neurotoxicity and chronic bilirubin encephalopathy 
• Chronic bilirubin encephalopathy: chronic and irreversible clinical neurologic 
sequelae associated with bilirubin neurotoxicity, including severe choreoathetoid 
cerebral palsy, sensorineural hearing loss, dental- enamel dysplasia, paralysis of 
upward gaze and intellectual deficits   
 
Scope of the Problem 
More than 60% of healthy full term and late preterm infants will develop 
hyperbilirubinemia during the first week of life. Most are discharged from their birth 
hospital before the peak of TSB occurs, usually at 72-120 hours of age. 
Hyperbilirubinemia typically resolves by 7-10 days of life. Approximately 5-11% of 
infants will develop severe hyperbilirubinemia. Without intervention, TSB levels can 
progress to values greater than 25 or 30 mg/dl (above the 99th percentile for age in hours) 
which puts the infant at risk for acute bilirubin encephalopathy and kernicterus. It is 
estimated that about one in seven infants with TSB levels greater than 30 mg/dl will 
develop kernicterus, resulting in chronic bilirubin encephalopathy.1,2 The relationship 
between extremely high TSB levels and bilirubin neurotoxicity is not known because 
routine surveillance is not available. Cases of extremely high levels of serum bilirubin in 
infants with no apparent sequelae have been reported. Conversely, infants without 
documented high serum bilirubin levels have been found to have kernicterus.3 The critical 
level in otherwise healthy newborns is likely influenced by postnatal age, maturity, 
duration of hyperbilirubinemia and rate of TSB rise. 
 
The current incidence of bilirubin encephalopathy in the US is unknown; however, 
kernicterus is still being reported. The majority of these affected infants are term and late-
preterm infants who are discharged from the hospital as healthy newborns, yet 
subsequently develop extreme hyperbilirubinemia and the neurodevelopmental findings 
associated with kernicterus. 
   
Current Guidelines for Management and Follow-Up  
In July 2004, the American Academy of Pediatrics (AAP) released a clinical practice 
guideline, “Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks 
of Gestation.”4 The focus of this guideline was to reduce the incidence of severe 
hyperbilirubinemia and bilirubin encephalopathy while minimizing the risks of unintended 
harm, such as maternal anxiety, decreased breastfeeding and unnecessary costs and 
treatment through appropriate identification, follow-up and therapy.  
 
The key elements of the AAP guideline are summarized in the following 
recommendations: 
1. Promote and support successful breastfeeding. 
2. Establish nursery protocols for the identification and evaluation of 
hyperbilirubinemia. 
3. Measure the total serum bilirubin (TSB) or transcutaneous bilirubin (TcB) level on 
infants jaundiced in the first 24 hours. 
4. Recognize that visual estimation of the degree of jaundice can lead to errors, 
particularly in darkly pigmented infants. 
5. Interpret all bilirubin levels according to the infant’s age in hours. (See Figure 2, 
AAP guideline4) 
6. Recognize that infants less than 38 weeks’ gestation, particularly those who are 
breastfed, are at higher risk of developing hyperbilirubinemia and require closer 
surveillance and monitoring. 
7. Perform a systematic assessment on all infants before discharge for the risk of 
severe hyperbilirubinemia. (See Table 2, AAP guideline4) 
8. Provide parents with written and verbal information about newborn jaundice. 
9. Provide appropriate follow-up based on the time of discharge and the risk 
assessment. 
10. Treat newborns, when indicated, with phototherapy or exchange transfusion. (See 
Figures 3 & 4, AAP guideline4)  
 
In 2009, a panel of experts reviewed the relevant literature including the report on 
screening for neonatal hyperbilirubinemia by the Tufts-New England Medical Center 
Evidence-Based Practice Center5 and the current report by the US Preventive Services 
Task Force.3 New evidence suggests that combining a predischarge measurement of TSB 
or TcB with clinical risk factors including gestational age might improve the prediction of 
the risk of subsequent hyperbilirubinemia.  In October 2009, Maisels et al published their 
commentary article, “Hyperbilirubinemia in the Newborn Infant >35 Weeks’ Gestation: 
An Update With Clarifications.”6 In addition to clarifying several areas addressed in the 
2004 AAP guideline, the authors introduced new recommendations for management and 
follow-up testing according to predischarge screening, gestation, and risk factors for 
subsequent hyperbilirubinemia. Their recommendations are summarized in Figure 3 of the 
guideline.6 The gestational age and the predischarge TSB or TcB level are the most 
important factors that help to predict the risk of hyperbilirubinemia. The risk increases 
with each decreasing week of gestation from 42-35 weeks.  
 
TcB Measurement 
TcB or transcutaneous bilirubin measurement is being performed more frequently in 
hospitals and outpatient settings. This noninvasive screening tool provides a good estimate 
of the TSB expressed in mg/dl and helps to determine whether the TSB should be 
measured. As with any point-of-care testing, regular monitoring for quality assurance by 
comparing TcB measurements with the TSB is necessary. Studies in term and late preterm 
infants have indicated that the TcB tends to underestimate the TSB, particularly at higher 
TSB levels. In the 2009 updated guidelines, Maisels et al provide specific evidence-based 
strategies for determining when TSB measurement is indicated.6  
 
Measurement of the TSB should be performed if: 
• The TcB value is at 70% of the TSB level recommended for the use of 
phototherapy7 
• The TcB value is above the 75th percentile on the Bhutani nomogram (Fig 1) or the 
95th percentile on a TcB nomogram8  
• At follow-up after discharge, the TcB value is >13mg/dl (222µmol/L)9  
 
Treatment 
In 2011, the AAP published a technical report, “Phototherapy to Prevent Severe Neonatal 
Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.”10 Their intent 
was to standardize the use of phototherapy in the management of hyperbilirubinemia. The 
most important intervention for infants with severe hyperbilirubinemia is to initiate 
phototherapy without delay. The clinical response to phototherapy depends on the efficacy 
of the phototherapy device, as well as the infant’s rates of bilirubin production and 
elimination. The following characteristics contribute to the effectiveness of the 
phototherapy device: emission of light in the blue-to-green range that overlaps the in vivo 
plasma bilirubin absorption spectrum (~460-490 nm); irradiance of at least 30 µW/cm2 per 
nm (confirmed with an appropriate irradiance meter calibrated over the appropriate 
wavelength range); illumination of maximal body surface; and demonstration of a 
decrease in total bilirubin concentrations during the first 4 to 6 hours of exposure. Serial 
measurements of bilirubin concentrations are recommended to monitor the effectiveness 
of phototherapy treatment.  
 
The efficacy of commercial neonatal phototherapy devices varies widely. These devices 
can be categorized according to their light source as follows: gallium nitride light-emitting 
diodes (LED), halogen spot lights (metal halide bulbs), fiberoptic blankets and fluorescent 
tube devices. The performance characteristics of the most commonly used phototherapy 
devices are summarized in Table 1 of the 2011 technical report.10 The AAP has 
recommended that the irradiance for intensive phototherapy be at least 30 µW/cm2 per nm 
over the wavelength band interval of 460-490 nm.4 Devices that emit lower irradiance may 
be supplemented with auxiliary devices. The AAP further recommends that “All nurseries 
and services treating infants should have the necessary equipment to provide intensive 
phototherapy.”4  
 
The AAP recommendations for exchange transfusion are summarized in Figure 4 of the 
2004 guidelines.4 During the birth hospitalization, exchange transfusion is recommended 
if the TSB rises to these levels despite intensive phototherapy. The following guidelines 
are provided for infants readmitted to the hospital with severe hyperbilirubinemia: if the 
TSB concentration is above the exchange level, repeat TSB measurement every 2 to 3 
hours and consider exchange transfusion if the TSB remains above the levels indicated 
after intensive phototherapy for 6 hours. Immediate exchange transfusion is recommended 
if the infant with hyperbilirubinemia shows signs of acute bilirubin encephalopathy: 
hypertonia, arching, retrocollis, opisthotonos, fever, high-pitched cry. 
 
In cases of isoimmune hemolytic disease, the AAP recommends administration of 
immunoglobulin (IgG, 0.5-1.0 g/kg over 2 hours) if the TSB is rising despite intensive 
phototherapy or the TSB level is within 2 to 3 mg/dl (34-51 µmol/L) of the exchange level 
(Fig 3). If necessary, this dose can be repeated in 12 hours.4  
 
Several pharmaceutical agents have been investigated for their ability to prevent or treat 
neonatal hyperbilirubinemia. Tin mesoporphyrin, a potent inhibitor of heme oxygenase, 
has been shown to effectively reduce TSB levels in term and preterm infants.  It is 
currently being investigated for use in infants with severe hyperbilirubinemia.12  
 
Parent Education and Resources 
Before the infant is discharged from the hospital, parents should be given both written and 
verbal information about newborn jaundice, including risk factors, identification and 
treatment. As part of their Safe and Healthy Beginnings program, the AAP offers a 
resource toolkit for hospitals and providers. “Safe & Healthy Beginnings: A Resource 
Toolkit for Hospital and Physician’s Offices” is based on the key aspects of the revised 
AAP hyperbilirubinemia guideline, including 1) the assessment of a newborn’s risk for 
severe hyperbilirubinemia, 2) support for breastfeeding mother, and 3) coordination of 
care between newborn nursery and primary care practice. It is available for purchase at the 
AAP Bookstore. This on-line resource includes tools for clinicians and parent handouts.  
An on-line demo is available at, http://www.aap.org/pubserv/shb/index.html. 
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